People with Alzheimer's disease who took the common supplement glucosamine were 25% more likely to die within five years than those who didn't. That's the key finding of a new study that my colleagues and I published in the ...
Jun 13, 2026
0
13
Some alkaline mineral and medicinal waters may weaken the enteric coating of medications within just a few minutes, potentially reducing their effectiveness, according to a new study by Semmelweis University. The study, published ...
Jun 10, 2026
0
13
A clinical trial led by researchers from Hospital Clínic de Barcelona, the August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC) compared the effectiveness ...
Jun 10, 2026
0
12
In a study published in The Lancet, researchers at The University of Texas Medical Branch (UTMB) report the development of new vaccines that, in animal testing, provided full protection against the deadly Andes hantavirus ...
Jun 12, 2026
0
9
GLP-1 medications are marketed to help you lose weight, but one may be better at it than the rest, according to a new meta-analysis from the University of Georgia.
Jun 15, 2026
0
8
Adults with obesity who lost weight with glucagon-like peptide-1 (GLP-1) receptor agonist medications significantly decreased their physical activity, which is essential to protect muscle, according to a study presented at ...
Jun 13, 2026
0
8
Researchers at the University of Maryland School of Medicine's Center for Vaccine Development and Global Health, or CVD, report encouraging results from an early clinical trial that tested a new dual vaccine against Lassa ...
Jun 9, 2026
0
7
A new pill developed by the British pharmaceutical firm AstraZeneca appears to help people lose a similar amount of weight as other oral GLP-1 drugs, trial results showed Monday.
Jun 9, 2026
0
7
In people with type 2 diabetes, semaglutide was associated with a 15% reduction in bone fractures and greater weight loss compared with other anti-obesity medications, according to a study presented at ENDO 2026, the Endocrine ...
Jun 14, 2026
0
7
Once-weekly cagrilintide, an amylin receptor agonist, plus semaglutide is efficacious for adults with type 2 diabetes inadequately controlled with diet and exercise, receiving metformin with or without a sodium glucose cotransporter ...
Jun 12, 2026
0
7
